Hikma Details Weekly Disclosure Plan as $250m Buyback Cuts Share Count

An announcement from Hikma Pharmaceuticals ( (GB:HIK) ) is now available.

Hikma Pharmaceuticals has provided an update on reporting arrangements for its recently launched $250 million share buyback, stating that future repurchases of ordinary shares will be disclosed weekly and no later than the end of the seventh trading day after each transaction, in line with U.K. market abuse and listing regulations. The company also reported that on 6 March 2026 it bought 251,580 shares at a volume-weighted average price of 1,224.70 pence, bringing total repurchases since 26 February to 1,578,744 shares costing £20 million, which will be cancelled, modestly reducing the share count and leaving 220,307,709 voting shares outstanding.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. The group focuses on injectable, branded and generic medicines, with a strong presence in the Middle East and North Africa as well as established operations in the U.K., U.S. and Europe.

Average Trading Volume: 1,105,333

Technical Sentiment Signal: Sell

Current Market Cap: £2.65B

For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.